Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs
Kenji Inoue1, Akira Setogawa1, Risako Higa1, Ryo Moriyama1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan; 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, JapanIntroduction: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e79031c01f814f9c9867b40e2370e08c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e79031c01f814f9c9867b40e2370e08c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e79031c01f814f9c9867b40e2370e08c2021-12-02T02:42:28ZOcular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs1177-54671177-5483https://doaj.org/article/e79031c01f814f9c9867b40e2370e08c2012-02-01T00:00:00Zhttp://www.dovepress.com/ocular-hypotensive-effect-and-safety-of-travoprost-0004timolol-maleate-a9243https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Kenji Inoue1, Akira Setogawa1, Risako Higa1, Ryo Moriyama1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan; 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, JapanIntroduction: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the adherence of patients to the administration protocol.Materials and methods: We studied 43 eyes from 43 patients diagnosed with primary open-angle glaucoma, who were using prostaglandin analogs and ß-blockers. The prostaglandin analogs and ß-blockers were discontinued, and the treatment regimen was changed to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops without any washout period. IOP before and at 1 month, 3 months, and 6 months after the treatment change was evaluated and compared. A questionnaire about protocol adherence was administered 1 month after the treatment change.Results: IOP was 15.7 ± 2.9 mmHg before the change, 15.5 ± 2.7 mmHg at 1 month after the change, 15.3 ± 3.6 mmHg at 3 months after the change, and 15.8 ± 3.2 mmHg at 6 months after the change, and none of the differences were significant (P = 0.191). The responses to the questionnaire showed that cases where eye drop administration was forgotten decreased after the treatment change. Moreover, because of changes in eye drops, 19.0% of patients had irritation. More than half (54.8%) of the patients preferred travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops. Seven patients (16.3%) discontinued eye drop use because of adverse reactions within 6 months after the change.Conclusion: When the treatment regimen was changed from prostaglandin analogs and ß-blockers to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops, administration protocol adherence increased and IOP was preserved; however, adverse reactions appeared in about 16% of the cases.Keywords: travoprost 0.004%/timolol maleate 0.5% fixed combination, ß-blockers, prostaglandin analog, change, intraocular pressureInoue KSetogawa AHiga RMoriyama RWakakura MTomita GDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 231-235 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Inoue K Setogawa A Higa R Moriyama R Wakakura M Tomita G Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs |
| description |
Kenji Inoue1, Akira Setogawa1, Risako Higa1, Ryo Moriyama1, Masato Wakakura1, Goji Tomita21Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan; 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, JapanIntroduction: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the adherence of patients to the administration protocol.Materials and methods: We studied 43 eyes from 43 patients diagnosed with primary open-angle glaucoma, who were using prostaglandin analogs and ß-blockers. The prostaglandin analogs and ß-blockers were discontinued, and the treatment regimen was changed to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops without any washout period. IOP before and at 1 month, 3 months, and 6 months after the treatment change was evaluated and compared. A questionnaire about protocol adherence was administered 1 month after the treatment change.Results: IOP was 15.7 ± 2.9 mmHg before the change, 15.5 ± 2.7 mmHg at 1 month after the change, 15.3 ± 3.6 mmHg at 3 months after the change, and 15.8 ± 3.2 mmHg at 6 months after the change, and none of the differences were significant (P = 0.191). The responses to the questionnaire showed that cases where eye drop administration was forgotten decreased after the treatment change. Moreover, because of changes in eye drops, 19.0% of patients had irritation. More than half (54.8%) of the patients preferred travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops. Seven patients (16.3%) discontinued eye drop use because of adverse reactions within 6 months after the change.Conclusion: When the treatment regimen was changed from prostaglandin analogs and ß-blockers to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops, administration protocol adherence increased and IOP was preserved; however, adverse reactions appeared in about 16% of the cases.Keywords: travoprost 0.004%/timolol maleate 0.5% fixed combination, ß-blockers, prostaglandin analog, change, intraocular pressure |
| format |
article |
| author |
Inoue K Setogawa A Higa R Moriyama R Wakakura M Tomita G |
| author_facet |
Inoue K Setogawa A Higa R Moriyama R Wakakura M Tomita G |
| author_sort |
Inoue K |
| title |
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs |
| title_short |
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs |
| title_full |
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs |
| title_fullStr |
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs |
| title_full_unstemmed |
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs |
| title_sort |
ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/e79031c01f814f9c9867b40e2370e08c |
| work_keys_str_mv |
AT inouek ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfromampszligblockersandprostaglandinanalogs AT setogawaa ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfromampszligblockersandprostaglandinanalogs AT higar ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfromampszligblockersandprostaglandinanalogs AT moriyamar ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfromampszligblockersandprostaglandinanalogs AT wakakuram ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfromampszligblockersandprostaglandinanalogs AT tomitag ocularhypotensiveeffectandsafetyoftravoprost0004timololmaleate05fixedcombinationafterchangeoftreatmentregimenfromampszligblockersandprostaglandinanalogs |
| _version_ |
1718402256352575488 |